Lyell Immunopharma, Inc. (LYEL) vs MacroGenics, Inc. (MGNX)
Lyell Immunopharma, Inc. and MacroGenics, Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. and MacroGenics, Inc. are of similar size ($248.0M and $242.1M). MacroGenics, Inc. grew revenue faster over the last twelve months: 21.9% against −55.0%. MacroGenics, Inc. has the higher net margin (−7.97% vs −920,285.2%) and the higher return on invested capital (0.00% vs −539.5%). Across the 17 metrics below, MacroGenics, Inc. leads on 12 and Lyell Immunopharma, Inc. on 5.
Valuation
Profitability
| Metric | LYEL | MGNX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 78.07% | 65.16% |
| Operating margin | (949,981.48%) | (18.73%) | 0.00% |
| Net margin | (920,285.19%) | (7.97%) | 0.00% |
| Free cash flow margin | (647,681.48%) | (35.80%) | 0.00% |
| Return on equity | (93.28%) | (32.61%) | (57.72%) |
| Return on assets | (71.34%) | (4.94%) | (49.22%) |
| Return on invested capital | (539.53%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack